Oxalate homeostasis.
Ermer T, Nazzal L, Tio MC, Waikar S, Aronson PS, Knauf F.
Nat Rev Nephrol. 2023 Feb;19(2):123-138. doi: 10.1038/s41581-022-00643-3. Epub 2022 Nov 3.
Stiripentol identifies a therapeutic target to reduce oxaluria.
Letavernier E, Daudon M.
Curr Opin Nephrol Hypertens. 2020 Jul;29(4):394-399. doi: 10.1097/MNH.0000000000000621.
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope.
Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, Beck BB, Boyer O, Cerkauskiene R, Ferraro PM, Groen LA, Gupta A, Knebelmann B, Mandrile G, Moochhala SS, Prytula A, Putnik J, Rumsby G, Soliman NA, Somani B, Bacchetta J.
Nat Rev Nephrol. 2023 Mar;19(3):194-211. doi: 10.1038/s41581-022-00661-1. Epub 2023 Jan 5.
Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.
Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M.
Am J Kidney Dis. 2022 May;79(5):717-727. doi: 10.1053/j.ajkd.2021.07.018. Epub 2021 Sep 9.
PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.
Baum MA, Langman C, Cochat P, Lieske JC, Moochhala SH, Hamamoto S, Satoh H, Mourani C, Ariceta G, Torres A, Wolley M, Belostotsky V, Forbes TA, Groothoff J, Hayes W, Tönshoff B, Takayama T, Rosskamp R, Russell K, Zhou J, Amrite A, Hoppe B; PHYOX2 study investigators.
Kidney Int. 2023 Jan;103(1):207-217. doi: 10.1016/j.kint.2022.07.025. Epub 2022 Aug 22.
Primary hyperoxaluria.
Lorenzo V, Torres A, Salido E.
Nefrologia. 2014 May 21;34(3):398-412. doi: 10.3265/Nefrologia.pre2014.Jan.12335. Epub 2014 Apr 30.
Future treatments for hyperoxaluria.
Burns Z, Knight J, Fargue S, Holmes R, Assimos D, Wood K.
Curr Opin Urol. 2020 Mar;30(2):171-176. doi: 10.1097/MOU.0000000000000709.
Pathophysiology and management of enteric hyperoxaluria.
Desenclos J, Forté V, Clément C, Daudon M, Letavernier E.
Clin Res Hepatol Gastroenterol. 2024 May;48(5):102322. doi: 10.1016/j.clinre.2024.102322. Epub 2024 Mar 19.
Ascorbate increases human oxaluria and kidney stone risk.
Massey LK, Liebman M, Kynast-Gales SA.
J Nutr. 2005 Jul;135(7):1673-7. doi: 10.1093/jn/135.7.1673.
Pathophysiology and management of enteric hyperoxaluria.
Joly PF.
Clin Res Hepatol Gastroenterol. 2024 Jun;48(6):102359. doi: 10.1016/j.clinre.2024.102359. Epub 2024 May 10.
